- Home
- SI vs ZNTL Comparison
SI vs ZNTL Comparison
Compare SI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | ZNTL |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 313.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SI | ZNTL |
|---|---|---|
| Price | $13.74 | $4.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $20.80 | $6.60 |
| AVG Volume (30 Days) | 54.7K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.59 | N/A |
| Revenue Next Year | $31.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.92 | $1.13 |
| 52 Week High | $17.23 | $6.95 |
Technical Indicators
Market Signals| Indicator | SI | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 53.02 |
| Support Level | $13.47 | $3.75 |
| Resistance Level | $13.63 | $4.34 |
| Average True Range (ATR) | 0.82 | 0.31 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 74.82 | 53.17 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.